Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
Diana Corona‐Mata(Instituto Maimónides de Investigación Biomédica de Córdoba), Antonio Rivero(University of Southern California), Ángela Gutiérrez(Hospital Universitario Puerta de Hierro Majadahonda), Inmaculada Jarrín(Instituto de Salud Carlos III), Ángela Camacho(Hospital Universitario Reina Sofía), Ignacio Valero(Instituto de Salud Carlos III), Marta Montero, María Remedios Alemán Valls, Pilar Ruíz-Seco(Hospital Universitario Infanta Sofía), Alexandre Pérez‐González(University Hospital Complex Of Vigo), Melchor Riera(Instituto de Salud Carlos III), Antonio Rivero‐Juárez(Instituto de Salud Carlos III)
Cited by 15
Related Papers
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
|Clinical Microbiology and Infection|2020|128